A 32-year-old woman from rural Maharashtra presents with a 3-week history of productive cough, low-grade fever, and night sweats. Chest X-ray shows a cavitary lesion in the right upper lobe. Sputum smear microscopy is positive for acid-fast bacilli (AFB). She is started on anti-TB therapy under RNTCP. After 2 months of Category 1 regimen (2HRZE/4HR), repeat sputum smear remains positive. What is the most appropriate next step in management according to NTEP guidelines?

Explanation

## Management of Treatment Failure in TB — NTEP Protocol **Key Point:** Persistent sputum positivity after 2 months of Category 1 therapy defines **treatment failure** and mandates investigation for drug resistance and possible MDR-TB. ### Definition of Treatment Failure According to NTEP guidelines, treatment failure is defined as: - Sputum smear or culture positive at 5 months or later during treatment - Alternatively, sputum positivity at 2 months in a patient who was initially smear-positive and has received at least 2 months of supervised therapy ### Appropriate Next Step 1. **Immediate action:** Refer for drug susceptibility testing (DST) to identify resistance pattern 2. **Rationale:** Continued positivity suggests either: - Non-adherence (less likely in supervised RNTCP setting) - Drug resistance (MDR-TB or XDR-TB) - Malabsorption or drug interactions 3. **Outcome:** Based on DST results, switch to appropriate second-line regimen (Category 2 or MDR-TB regimen) ### Why Category 2 is NOT Immediate **Clinical Pearl:** Category 2 (2HRZES/1HRZE/5HR) is reserved for **relapse cases**, not primary treatment failure. Primary treatment failure with persistent AFB positivity suggests drug resistance, not simple relapse. ### NTEP Treatment Categories | Category | Indication | Regimen | |----------|-----------|----------| | Category 1 | New TB (smear+/−) | 2HRZE/4HR | | Category 2 | Relapse, treatment after default | 2HRZES/1HRZE/5HR | | MDR-TB | Resistant to INH + RIF | Longer regimen with fluoroquinolone + injectable | | XDR-TB | Resistant to first-line + fluoroquinolone | Newer drugs (bedaquiline, linezolid) | **High-Yield:** Treatment failure = DST + second-line therapy, not continuation or category change without investigation. ### Clinical Pearl In RNTCP, all cases of suspected treatment failure must have sputum sent for culture and DST before any regimen change. This prevents unnecessary escalation and ensures targeted therapy based on resistance pattern.